woman jumping in the air with words in a circle that say Prevention is possible

GLOBALLY DEVELOPING IN VITRO RNA TECHNOLOGYOur Mission

Mel-Mont Medical specializes in designing, developing, and marketing state-of-the-art technologies and medical services that preserve life through the prevention and early diagnosis of RNA-virus-related pathologies. Our experienced team and top-end equipment ensure the safety and confidence of our patients.

View Research & Development

PATENTED DEVICES AND MOLECULAR TECHNOLOGIESOur Vision

To be leaders in molecular testing by managing a diversified portfolio of proprietary technologies and medical devices for secondary prevention and early identification of DNA and RNA virus-related pathologies (HPV, respiratory viruses).

  • rocket ship icon 2014

    Mel-Mont Medical commences operations with its medical device Mia by XytoTest®

  • Colombia Icon with flag 2015

    Mía by XytoTest® receives regulatory authorization (INVIMA) in Colombia.

  • Mexico icon with flag 2016

    Mía by XytoTest® completes phase II clinical trials and receives regulatory authorization (COFEPRIS) in Mexico.

  • USA icon with flag 2017

    Mía by XytoTest® launches on the Mexican market. Regulatory authorization awarded (CE Marking) in Europe.

  • Spain icon with flag 2018

    Mel-Mont Medical launches a subsidiary, MHS Farma 72, in Mallorca, Spain, to market Mía by XytoTest® and to offer a molecular laboratory service.

  • Norway icon with flag 2020

    Gedeon Richter is granted exclusive distribution rights of Mía by XytoTest® for the Spanish market. Mel-Mont Medical acquires PreTect, Norway.

  • 2021

    Mel-Mont Medical signs MTA with USN for the shared sequences of ORF1ab. Mel-Mont acquires MC² Molecular Laboratory (Spain) and initiates the development of a new assay for the detection of Sars-CoV-2 / Influenza A/B based on mRNA technology.

Our TeamWho We Are

Frank Melendez Frank Melendez Chief Executive Officer
Frank Melendez

Frank Melendez

Chief Executive Officer

Frank is an entrepreneur with a hugely successful background in innovative medical devices (Class II). He has taken these new medical technologies to market following stringent adherence to the framework for new product development, which encompasses design, development, copyright protection, clinical trials, regulatory authorizations, and global marketing in 18 countries. Frank invented the Hemor-Rite cryotherapy device, which reached sales of 18 million US dollars before he left the company in 2013. Since then, he has focused on developing and growing his new business project, Mel-Mont Medical, where he is the coinventor of products like Mia by XytoTest® and AnalTest®.

Education:
Degree in Business Administration, La Salle University, Colombia
MBA in Trade Marketing, Pontificia Universidad Javeriana, Bogotá – Colombia
MSc in Engineering Business Management, University of Warwick, United Kingdom

Liliana Montes Liliana Montes Chief Operations Officer
Liliana Montes

Liliana Montes

Chief Operations Officer

Liliana is an entrepreneur and senior partner at OncoTech for clinical trial management. She is the coinventor of two patented medical devices, one of which is Mía by XytoTest®, a Class II medical device for cervical cancer prevention. Liliana used her expertise in process management and standardization, regulatory compliance, preclinical and clinical validation, and global logistics to successfully take this product to market. She has also worked as an international consultant in process standardization, and the development and rollout of quality management systems, and as quality coordinator for one of Colombia’s best-known pharmacy chains.

Education:
Degree in Industrial Engineering, Pontificia Universidad Javeriana, Cali, Colombia
MSc in Engineering Business Management, University of Warwick, United Kingdom
Certification as an ISO 9001 external auditor, Pontificia Universidad Javeriana, Cali, Colombia

Octavio Gonzalez Octavio Gonzalez Peredo Chief Commercial Officer
Octavio Gonzalez

Octavio Gonzalez Peredo

Chief Commercial Officer

Octavio is a businessman, lawyer, and professor, with studies in top-tier management, and has over 10 years’ professional experience in business development in the Mexican and international pharmaceutical industries. He has successfully managed commercial transactions related to drugs, wound dressing materials, clinical protocols, and nationwide distribution and operations, as well as representing transnational laboratories in Mexico.

He is an entrepreneur with a strong sense of ethical and professional integrity, and a pharmaceutical supply chain expert, creating high-performance business models. He excels in opportunity identification, strategic negotiations, team leadership, and networking with top-tier leaders in public and private hospitals, medical societies, and distributors.

Education:
Degree in Law, Universidad Panamericana, Mexico
MSc in International Business and Management, University of Manchester, United Kingdom
AD Senior Management Program, IPADE Business School, Mexico

Michael R. Torres Chief Financial Officer

Michael R. Torres

Chief Financial Officer

Michael is a partner at the public accounting firm PAAST. He has over 25 years of experience providing tax, accounting, attestation, business consulting, and forensic accounting services to clients in various industries such as financial services, investment funds, manufacturing, pharmaceutical, technology, and health care. Michael’s experience includes preparing business plans for mergers and acquisitions, financial reporting, SEC filing requirements, performing internal and external audits and operational reviews, and tax planning and strategies. Prior to starting his own public accounting firm, Michael was the vice president of finance for Marex, a NASDAQ listed company, and an audit senior at Arthur Andersen.

Michael Friedman, MD Scientific Advisor

Michael Friedman, MD

Scientific Advisor

Dr. Friedman is the emeritus Chief Executive Officer of City of Hope, a leading cancer research, treatment and education institution, as well as Director of the organization’s Comprehensive Cancer Center and holder of the Irell & Manella Cancer Center Director’s Distinguished Chair. Before leading City of Hope, Dr. Friedman was Senior Vice President of Research and Development, Medical and Public Policy for Pharmacia Corporation and Chief Medical Officer for biomedical preparedness at PhRMA. Additionally, Dr. Friedman has served as Deputy Commissioner for the U.S. Food and Drug Administration (FDA), as Acting Commissioner, and also as Associate Director of the National Cancer Institute, National Institutes of Health. Since 2004, Dr. Friedman has sat on the Independent Citizens’ Oversight Committee which governs the California Institute for Regenerative Medicine and oversees the implementation of California’s stem cell research effort. Dr. Friedman is a member of the Board of Directors of MannKind Corporation, Celgene Corporation, Smith & Nephew plc, and Intuitive Surgical Corporation. He also serves on the Board of Trustees for Tulane University and the California State Stem Cell Initiative. Dr. Friedman successfully combines scientific and operational expertise with leadership skills from his extensive background in cancer research and public health as a senior officer of a leading research institution, deputy and acting commissioner of the FDA, and as an executive officer of a major pharmaceutical company.

Bente Marie Falang Bente Marie Falang Director of the In Vitro Division
Bente Marie Falang

Bente Marie Falang

Director of the In Vitro Division

Bente Marie Falang became PreTect CEO in February 2016, after working as Laboratory Manager since 2004, with several roles in production, R&D, and QA. She has 30 years’ extensive practical experience in the biomedical industry participating in the development of molecular diagnostic methods. Before joining PreTect, she spent 10 years in a research group at the National Hospital of Norway (Rikshospitalet), focusing on immunological techniques. Bente Marie holds a B.Sc degree in biomedical laboratory engineering from Rikshospitalet in Oslo.

Bente Marie has special expertise in Molecular Diagnostic Methods, Scientific Research, Clinical Studies, Human Papilloma Virus (HPV) mRNA, Electronic Quality Manual System (eQMS), ISO 13485:2016, GMP, GLP, Customer Support, Positive Leadership, and General Management.

Imanol Mangado Imanol Mangado Managing Director for Europe
Imanol Mangado

Imanol Mangado

Managing Director for Europe

Imanol has extensive professional experience in the pharmaceutical industry. In his early career, for seven years he was the financial director of BioWise Pharmaceuticals, a pharmaceutical generics laboratory specializing in urology. After becoming assistant director, he launched the Portuguese subsidiary for OTC products and took the helm for the corporate restructuring of the group in the wake of a merger by takeover. Imanol is also experienced in auditing and accounting consolidation.

His skillset includes personnel management and business planning, but his forte is accounting management and financial planning for international companies.

Education:
Graduate in Business Sciences from the University of the Balearic Islands, Spain
MBA in Business Administration from IESEM Business School, Nebrija University, Madrid

Alejandro Melendez Alejandro Melendez Global Business Development Manager
Alejandro Melendez

Alejandro Melendez

Global Business Development Manager

Alejandro has a successful commercial background in medical devices and pharmaceutical products and has launched many new and innovative products in the Caribbean and European markets. A skilled approach to building and maintaining relations has expanded his business portfolio with high-level contacts in Europe. His tenacity and humanitarian spirit have inspired him to help not-for-profit organizations benefit from the technologies he has marketed, thereby enabling them to provide their patients with the best possible care.

Education:
Bachelor in Business Administration in International Business, Florida International University, Miami, USA
Certificate in Management, HBX Harvard Business School, Boston, Massachusetts

Robert B. (Rob) Dellenbach General Counsel

Robert B. (Rob) Dellenbach

General Counsel

Rob acts as the company’s general legal counsel. Rob founded Dellenbach Venture Counsel in 2013 and serves the company through his firm. Previously, Rob was a partner at Reed Smith LLP and Fenwick & West LLP and has worked with innovative companies such as Mel-Mont Medical, Inc., and with ventures in Silicon Valley and around the globe for more than thirty years.

FIND USBroadening Horizons

We are a growing multinational company with subsidiaries and strategic relationships in the Americas and Europe.

United States 11467 NW 34th Street
Doral, FL 33178 Tel: +1 305 335 6162
Mexico (Exclusive Distributor) Laguna de Términos 221. Int 1104
Col. Granada, Mexico City Tel: +52 55 4163 4414
Colombia (3rd Party Manufacturer) Carrera 7d Bis # 69a – 30
Cali, Valle Tel: +57 317 64 01217
Spain Calle Camilo José Cela 20
07014, Palma Tel: +34 677 85 28 81
Norway Ustadhagan 8
N-3490 KLOKKARSTUA Tel: +47 32 79 88 00
Contact Us

Have Questions? Our team is happy to answer any questions you may have.

Contact Us